title: Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions.
abstract: Several different oncogenes and growth factors promote G1 phase progression. Cyclin D1, the regulatory subunit of several cyclin-dependent kinases, is required for, and capable of shortening, the G1 phase of the cell cycle. The present study demonstrates that transforming mutants of p21ras (Ras Val-12, Ras Leu-61) induce the cyclin D1 promoter in human trophoblasts (JEG-3), mink lung epithelial (Mv1.Lu), and in Chinese hamster ovary fibroblast cell lines. Site-directed mutagenesis of AP-1-like sequences at -954 abolished p21ras-dependent activation of cyclin D1 expression. The AP-1-like sequences were also required for activation of the cyclin D1 promoter by c-Jun. In electrophoretic mobility shift assays using nuclear extracts from cultured cells and primary tissues, several AP-1 proteins (c-Jun, JunB, JunD, and c-Fos) bound the cyclin D1 -954 region. Cyclin D1 promoter activity was stimulated by overexpression of mitogen-activated protein kinase (p41MAPK) or c-Ets-2 through the proximal 22 base pairs. Expression of plasmids encoding either dominant negative MAPK (p41MAPKi) or dominant negatives of ETS activation (Ets-LacZ), antagonized MAPK-dependent induction of cyclin D1 promoter activity. Epidermal growth factor induction of cyclin D1 transcription, through the proximal promoter region, was antagonized by either p41MAPKi or Ets-LacZ, suggesting that ETS functions downstream of epidermal growth factor and MAPK in the context of the cyclin D1 promoter. The activation of cyclin D1 transcription by p21ras provides evidence for cross-talk between the p21ras and cell cycle regulatory pathways.
authors.affiliation: Division of Endocrinology, Metabolism, and Molecular Medicine, Northwestern University Medical School, Chicago, Illinois 60611, USA.
authors.forename: C
authors.initials: C
authors.lastname: Albanese
authors.forename: J
authors.initials: J
authors.lastname: Johnson
authors.forename: G
authors.initials: G
authors.lastname: Watanabe
authors.forename: N
authors.initials: N
authors.lastname: Eklund
authors.forename: D
authors.initials: D
authors.lastname: Vu
authors.forename: A
authors.initials: A
authors.lastname: Arnold
authors.forename: R G
authors.initials: RG
authors.lastname: Pestell
mesh_terms: D000818:Animals; D001483:Base Sequence; D017871:Calcium-Calmodulin-Dependent Protein Kinases / Q000378:metabolism; D002460:Cell Line; D006224:Cricetinae; D019938:Cyclin D1; D016213:Cyclins / Q000235:genetics*; D004247:DNA / Q000235:genetics; D004268:DNA-Binding Proteins; D016193:G1 Phase / Q000235:genetics; D005786:Gene Expression Regulation; D011905:Genes, ras; D006801:Humans; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D015513:Oncogene Proteins / Q000235:genetics*; D017354:Point Mutation; D011401:Promoter Regions, Genetic; D050787:Proto-Oncogene Protein c-ets-2; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016755:Proto-Oncogene Proteins c-jun / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras) / Q000235:genetics*; D012097:Repressor Proteins; D015534:Trans-Activators / Q000235:genetics*; D018808:Transcription Factor AP-1 / Q000378:metabolism; D014157:Transcription Factors; D014170:Transformation, Genetic
chemical_list: D016213:Cyclins; D004268:DNA-Binding Proteins; C107465:ERF protein, human; C494069:ETS2 protein, human; D015513:Oncogene Proteins; D050787:Proto-Oncogene Protein c-ets-2; D011518:Proto-Oncogene Proteins; D016755:Proto-Oncogene Proteins c-jun; D012097:Repressor Proteins; D015534:Trans-Activators; D018808:Transcription Factor AP-1; D014157:Transcription Factors; D019938:Cyclin D1; D004247:DNA; D017871:Calcium-Calmodulin-Dependent Protein Kinases; C501009:HRAS protein, human; D016283:Proto-Oncogene Proteins p21(ras)